NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading CTSO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is characterized as a turnaround, as CTSO is currently loss-making and working towards breakeven. The thesis is in a cautious state, with management focused on improving financial performance amidst high risks.
The market seems to have priced in a level of fragility, but it is currently viewed as justified and relatively cheap compared to peers. There is a notable expectations gap, indicating that the market may be anticipating further challenges.
Management is on track to achieve operating cash flow breakeven by the second half of 2026, but recent financial performance shows limited progress in gross margins and revenue growth. The near-term risk is elevated, with a significant probability of missing expectations.
The future performance of CTSO will depend on management's ability to meet their cash flow goals and improve margins. Additionally, the performance of sector bellwethers like ABT, SYK, and MDT will influence the overall healthcare sector momentum and CTSO's position within it.
Over the next 1 to 3 years, CTSO's trajectory will be closely tied to its operational improvements and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. There are no new strengths or weaknesses identified that would alter the current assessment. The recent financial performance remains steady, but it continues to sit below its industry cohort, which is worth monitoring.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if the company is getting closer to cash flow breakeven. Investors will look for signs of improvement.
Confirms one read:Operating cash flow improves to less negative than -$1.2M in Q2 2026.
Confirms the other:Operating cash flow worsens or stays more negative than -$1.2M in Q2 2026.
Why it matters: Fixing the Nasdaq compliance issue is important to keep the listing. It affects investor trust and capital access.
Confirms:Nasdaq confirms compliance with listing rules before the deadline.
Disproves:More notices or actions from Nasdaq about delisting.
Why it matters: Getting back in line with Nasdaq is important to keep the stock listed. This impacts how investors feel.
Confirms:The company needs a minimum bid price of $1.00 for 10 days before September 28.
Disproves:The stock price remains below $1.00 without regaining compliance by September 28.
Why it matters: The earnings report will show if CytoSorbents can improve its financial performance. Investors will look for signs of recovery.
Confirms one read:The earnings report shows revenue growth or smaller losses than last quarter.
Confirms the other:The earnings report shows more losses or less revenue than last quarter.
Why it matters: Improving gross margins are key to the company's financial health. It will show if cost control efforts are working.
Confirms:Gross profit in Q2 2026 increases from $6.1M in Q1 2026.
Disproves:Gross profit in Q2 2026 declines further from $6.1M in Q1 2026.
Why it matters: If healthcare sector growth speeds up, it could help CytoSorbents improve its performance. It shows the market is strengthening.
Confirms:Healthcare sector revenue growth speeds up to 10% or more.
Disproves:Healthcare sector revenue growth continues to slow or stays below 10%.
Why it matters: Stable or rising revenue is important for the company's growth story. It shows demand for key clinical uses.
Confirms:Q2 revenue shows growth or stabilizes compared to Q1.
Disproves:Q2 revenue declines further from Q1.
Why it matters: Getting to cash flow breakeven is important for financial health. It shows good cost and operations management.
Confirms:Q2 operating cash flow reaches breakeven or better.
Disproves:Q2 cash flow is still negative. It got worse compared to Q1.
Why it matters: This submission is important for more chances in cardiac surgery. Approval could lead to more money.
Confirms:The new De Novo application for DrugSorb-ATR is due by the end of 2026.
Disproves:Failure to submit the new De Novo application by the end of 2026.
